Edition:
United Kingdom

Catabasis Pharmaceuticals Inc (CATB.OQ)

CATB.OQ on NASDAQ Stock Exchange Global Market

1.72USD
6:05pm GMT
Change (% chg)

$0.05 (+2.69%)
Prev Close
$1.67
Open
$1.66
Day's High
$1.80
Day's Low
$1.63
Volume
163,364
Avg. Vol
114,877
52-wk High
$3.78
52-wk Low
$1.09

Chart for

About

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer... (more)

Overall

Beta: --
Market Cap(Mil.): $55.98
Shares Outstanding(Mil.): 22.48
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Corriente Advisors Reports 7.3 Pct Passive Stake In Catabasis Pharmaceuticals‍​

* CORRIENTE ADVISORS LLC REPORTS 7.3 PERCENT PASSIVE STAKE IN CATABASIS PHARMACEUTICALS INC AS OF FEBRUARY 16, 2018 - SEC FILING‍​ Source text : (http://bit.ly/2CDqdMi) Further company coverage:

1:46pm GMT

BRIEF-Catabasis Reports Edasalonexent Preserved Muscle Function And Substantially Slowed Duchenne Muscular Dystrophy Disease Progression

* CATABASIS PHARMACEUTICALS REPORTS EDASALONEXENT PRESERVED MUSCLE FUNCTION AND SUBSTANTIALLY SLOWED DUCHENNE MUSCULAR DYSTROPHY DISEASE PROGRESSION THROUGH MORE THAN ONE YEAR OF TREATMENT

13 Feb 2018

BRIEF-Catabasis Pharmaceuticals reports third quarter financial results

* Catabasis Pharmaceuticals reports third quarter 2017 financial results and reviews business progress

09 Nov 2017

BRIEF-Catabasis Pharmaceuticals reports positive results from phase 2 trial of medicine for progressive muscle degeneration disease

* Catabasis Pharmaceuticals reports positive results from open-label extension of phase 2 movedmd® trial evaluating Edasalonexent in duchenne muscular dystrophy and plans to initiate phase 3 clinical trial in first half 2018

04 Oct 2017

Earnings vs. Estimates